

## [340] INNOVATIVE NANO-CARRIERS FOR IMPROVED DELIVERY AND DRUG PERFORMANCE

Alon Moran<sup>1</sup>, Amit Badihi<sup>1</sup>, <sup>1</sup> Bionanosim

ABSTRACT TEMPLATE for Company Presentations

Questions for Biotech/Pharma; Medical Devices and Health IT/Digital Health categories are:

- **Investment Rational**

Based on decades of research by its founder and chairman, Prof. Simon Benita, inventor of Ikervis™ -a leading ophthalmological anti-inflammatory nano-emulsion, BNS has developed a proprietary technology platform for nano-encapsulation of existing drugs thereby generating proprietary new therapeutic entities (NTE). BNS holds a pipeline of NTEs in the fields of anti-cancer systemic therapy, skin inflammation and ophthalmic topical treatments. Generating revenues from various collaborations and out-licensing agreements, BNS represents a balanced risk investment profile, management proven track record both on the technological and commercial aspects and a diversified product portfolio.
- **Business Strategy**

BNS is engaged with a few out-licensing and collaboration agreement alliances with biopharma companies in which BNS is responsible for Drug Substance nano-carrier development while the partner is responsible for other product development activities as well as commercialization. At the same time, BNS is independently developing some of its portfolio products, thereby a blend of short, mid and long-term revenues and milestones are used to reduce risk and generate technological and business flexibility.
- **Core Technology**

Proprietary nano-encapsulation of drugs with Poly Lactic Glycolic Acid (PLGA) thereby improving the delivery profiles and drug performance of small molecules and peptide-based drugs as well as nano-carriers manufacturing upscaling are at the core competence of BNS.
- **Product Profile/Pipeline**

BNS leading products are improved version of Oxaliplatin a powerful chemotherapeutic agent to be used in hard to treat cancers, cyclosporine A (CsA) nanocapsules (NCs) topical formulation- elicited improved efficacy as compared to other treatments in terms of reduced skin inflammation and better preservation of the skin barrier integrity- developed under collaboration with another biopharma company, nano-encapsulated CBD (cannabidiol) for topical inflammatory conditions developed in collaboration with a leading cannabis development company, Tacrolimus NCs exhibited improved corneal adherence and better permeation in inflammatory eye disorders.
- **What's Next?**

Entering clinical testing in early 2019.